Takeda Pharmaceutical (NYSE:TAK) Insider Sells 34,535 Shares of Stock

Key Points

• Takeda insider Lauren Duprey sold 34,535 shares at an average price of $18.54, generating approximately $640,279. Following the sale, she retained 191,522 shares, a 15.28% reduction in her position.
• Takeda shares rose 0.6% to $18.71, near the company’s 12-month high of $18.90. The stock has a $59.95 billion market capitalization and trades at a price-to-earnings ratio of 55.03.
• Takeda’s latest quarterly results exceeded expectations, with $0.95 in earnings per share versus the $0.41 consensus estimate and revenue of $7.50 billion. Analyst sentiment has improved, with the stock carrying an overall “Buy” rating.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Lauren Duprey sold 34,535 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the transaction, the insider directly owned 191,522 shares of the company's stock, valued at $3,550,817.88. This represents a 15.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Lauren Rusckowski Duprey also recently made the following trade(s):

• On Monday, August 10th, Lauren Duprey sold 47,586 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total value of $813,720.60.

Takeda Pharmaceutical Stock Up 0.6%

TAK stock traded up $0.11 during midday trading on Tuesday, hitting $18.71. 2,678,363 shares of the company's stock were exchanged, compared to its average volume of 2,044,457. The firm has a 50 day moving average price of $17.58 and a 200-day moving average price of $17.19. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90. The stock has a market capitalization of $59.95 billion, a price-to-earnings ratio of 55.03 and a beta of -0.07. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.95 earnings per share for the quarter, topping analysts' consensus estimates of $0.41 by $0.54. The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, analysts anticipate that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of large investors have recently bought and sold shares of TAK. SHP Wealth Management bought a new stake in Takeda Pharmaceutical in the fourth quarter worth about $42,000. Manchester Capital Management LLC boosted its position in shares of Takeda Pharmaceutical by 91.4% during the 4th quarter. Manchester Capital Management LLC now owns 4,649 shares of the company's stock valued at $72,000 after purchasing an additional 2,220 shares in the last quarter. Harbour Investments Inc. grew its stake in shares of Takeda Pharmaceutical by 300.3% in the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company's stock worth $72,000 after purchasing an additional 3,460 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of Takeda Pharmaceutical by 30.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company's stock worth $81,000 after purchasing an additional 1,215 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in shares of Takeda Pharmaceutical by 3,783.0% in the 4th quarter. TD Private Client Wealth LLC now owns 9,824 shares of the company's stock worth $153,000 after purchasing an additional 9,571 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on TAK shares. Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Weiss Ratings raised Takeda Pharmaceutical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday. Finally, Zacks Research upgraded Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Japan. The company researches, develops, manufactures and markets prescription medicines and vaccines for patients and healthcare professionals around the world.

Takeda focuses on several therapeutic areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Ninlaro for multiple myeloma and Iclusig for certain blood cancers, along with other specialty medicines and vaccines.

Founded in Osaka in 1781, Takeda has grown from a traditional pharmaceutical distributor into an international biopharmaceutical company serving markets across Japan, North America, Europe and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.